Pharmacotherapy of personality disorders: Methodological issues and results;Les traitements pharmacologiques des troubles de la personnalite: Aspects methodologiques et revue des resultats obtenus

Encephale

Volumn 25, Issue 5, 1999, Pages 496-507

  Pelissolo, A ^a   Lepine, J P ^a  

^a HÔPITAL FERNAND WIDAL   (France)

Author keywords

Personality disorders; Pharmacotherapy; Temperament

Indexed keywords

AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROFAROMINE; CARBAMAZEPINE; FLUOXETINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; PHENELZINE; SEROTONIN UPTAKE INHIBITOR; TIOTIXENE; TRIFLUOPERAZINE; VALPROIC ACID;

DRUG THERAPY; HUMAN; PERSONALITY DISORDER; QUESTIONNAIRE; RATING SCALE; REVIEW;

ANTIDEPRESSIVE AGENTS; EXTRAVERSION (PSYCHOLOGY); HUMANS; MMPI; PERSONALITY DISORDERS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS;

EID: 0032752855     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. AKISKAL HS. Dysthymic disorders : psychopathology of proposed chronic subtypes. Am J Psychiatry 1983 ; 140 : 11-20.
2. AKISKAL HS. The prevalent clinical spectrum of bipolar disorders : beyond DSM IV. J Clin Psychopharmacol 1996 ; 16 (2 Suppl 1 ) : 4S-14.
3. ALLGULLANDER C, CLONINGER CR, PRZYBECK TR et al. Changes on the Temperament and Character Inventory after paroxetine treatment in volunteers with generalized anxiety disorder. Psychopharmacol Bull 1997 ; 34 : 165-6.
4. ALLILAIRE JF. Les états limites : antidépresseurs intermittents ou au long cours ? Encephale 1996 ; Sp 1: 45-8
5. AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997; 36 (10 Suppl) :85S-121.
6. ANSSEAU M. Intėrêt des antidépresseurs sérotoninergiques dans la personnalité obsessionnelle. Encephale 1996 ; 22 : 309-10.
7. BECK AT, FREEMAN A AND ASSOCIATES. Cognitive therapy of personality disorders. New York : The Guilford Press, 1990.
8. BLACK KJ, SHELINE YI. Personality disorder scores improve with effective pharmacotherapy of depression. J Affect Dis 1997 ; 43 : 11-8.
9. BROWN SL, SVRAKIC DM, PRZYBECK TR et al. The relationship of personality to mood and anxiety states : a dimensional approach. J Psychiatric Res 1992 ; 26 :197-211.
10. CAMPBELL M, COHEL IL, SMALL AM. Drugs in aggressive behavior. J Am Acad Child Psychiatry 1982 ; 21 : 107-17.
11. CAMPBELL M, SMALL AM, GREEN WH et al. Behavioral efficacy of haloperidol and lithium carbonate. Arch Gen Psychiatry 1984 ; 41 : 450-6.
12. CLONINGER CR. A systematic method for clinical description and classification of personality variants. Arch Gen Psychiatry 1987 ; 44 : 573-88.
13. CLONINGER CR, SVRAKIC DM, PRZYBECK TR. A psychobiological model of temperament and character. Arch Gen Psychiatry 1993 ; 50 : 975-90.
14. COCCARO EF, ASTILL JL, HERBERT J et al. Fluoxetine treatment of impulsive aggression in DSM III-R personality disorder patients. J Clin Psychopharmacol 1990 ; 10 : 373-5.
15. COCCARO EF, KAVOUSSI RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 1997 ; 54 : 1081-98.
16. COCCARO EF. Neurotransmitter function in personality disorders. In : Silk KR, ed. Biology of personality disorders. Washington : American Psychiatric Press, 1998 ; 1-25.
17. CORNELIUS JR, SOLOFF PH, PEREL JM et al. A preliminary trial of fluoxetine in refractory borderline patients. J Clin Psychopharmacol 1991 ; 11 : 116-20.
18. CORNELIUS JR, SOLOFF PH, PERELJM et al. Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. Am J Psychiatry 1993 ; 150 :1843-8.
19. COTTRAUXJ, BLACKBURN IM. Thérapies cognitives des troubles de la personnalité. Paris : Massen, 1995 ; 244 p.
20. COWDRY RW, GARDNER DL. Pharmacotherapy of borderline personality disorder : alprazolam, carbamazepine, trifluperazine, and tranylcypromine. Arch Gen Psychiatry 1988 ; 13 : 855-93.
21. DELTITO JA, STAM M. Psychopharmacological treatment of avoidant personality disorder. Compr Psychiatry 1989 ; 30 : 498-504.
22. EICHELMAN B. Toward a rational pharmacotherapy for aggressive and violent behavior. Hosp Community Psychiatry 1988 ; 39 : 31-9.
23. ENDICOTT J, SHEA MT. Measurement of change in personality disorders. Psychopharmacol Bull 1989 ; 25 : 572-7.
24. FAHLEN T. Personality traits in social phobia, II : changes during drug treatment. J Clin Psychiatry 1995 ; 56 : 569-73.
25. FAVA M. Psychopharmacologic treatment of pathologic aggression. Psychiatr Clin North Am 1997 ; 20 : 427-51.
26. FERROR T, KLEIN DN, SCHWARTZ JE et al. 30-month stability of personality disorder diagnoses in depressed outpatients. Am J Psychiatry 1998 ; 155 : 653-9.
27. GARDNER DL, COWDRY RW. Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder. Am J Psychiatry 1986; 143: 519-22.
28. GITLIN MJ. Pharmacotherapy of personality disorders : conceptual framework and clinical strategies. J Clin Psychopharmacol 1993 ; 13: 343-53.
29. GOLDBERG SC, SCHULZ SC, RESNICK RJ et al. Differential prediction of response to thiothixene and placebo in borderline and schizotypal personality disorders. Psychopharmacol Bull 1986 ; 23 : 342-6.
30. GUELFI JD, SIMON M, GILLET I. MMPI et MMPI-2. In : Guelfi JD, Gaillac V, Dardennes R. Psychopathologie quantitative. Paris : Masson, 1995; 77-91.
31. HAWTON K, ARENSMAN E, TOWNSEND E et al. Deliberate self harm : systematic review of psychosocial and pharmacological treatments in preventing repetition. Br Med J 1998 ; 317 : 441-7.
32. HEUMAN KA, MOREY LC. Reliability of categorical and dimensional judgments of personality disorder. Am J Psychiatry 1990 ; 147 : 498-500.
33. HIRSCHFELD RMA, KLERMAN GL, CLAYTON PJ et al. Assessing personality : effects of the depressive state on trait measurement. Am J Psychiatry 1983 ; 140 : 695-9.
34. HOLT CS, HEIMBERG RG, HOPE DA. Avoidant personality disorder and the generalized subtype of social phobia. J Abnorm Psychol 1992; 101 : 318-25.
35. HYLER SE, SKODOL AE, KELLMAN HD et al. Validity of the Personality Diagnostic Questionnaire-Revised : comparison with two structured interviews. Am J Psychiatry 1990 ; 147 : 1043-8.
36. HYMOWITZ P, FRANCES A, JACOBSBERG LB et al. Neuroleptic treatment of schizotypal personality disorders. Compr Psychiatry 1986 ; 27 : 267-71.
37. JENSEN HV, ANDERSEN J. An open, non comparative study of amoxapine in borderline disorders. Acta Psychiatr Scand 1989 ; 79 : 89-93.
38. JOFFE RT, BAGBY M, LEVITT AJ et al. The Tridimensional Personality Questionnaire in major depression. Am J Psychiatry 1993; 150 : 959-60.
39. JOUVENT R. De l'approche dimensionnelle à l'étude transnosograpnique des psychotropes. Encephale 1995 ; Sp 1: 39-43.
40. KAVOUSSI RJ, LIU J, COCCARO EF. An open trial of sertraline in personality disordered patients with impulsive aggression. J Clin Psychiatry 1994 ; 55 : 137-41.
41. KOCSIS JH, ZISOOK S, DAVIDSON J et al. Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia : psychosocial outcomes. Am J Psychiatry 1997 ; 154 : 390-5.
42. KRAMER PD. Listening to Prozac : a psychiatric explores mood-altering drugs and the new meaning of the Self. New York : Viking, 1993.
43. LEONE NF. Response of borderline patients to loxapine and chlorpromazine. J Clin Psychiatry 1982 ; 43 : 148-50.
44. LIEBOWITZ MR, KLEIN DF. Interrelationship of hysteroid dysphoria and borderline personality disorder. Psychiatr Clin North Am 1981 ; 4: 67-87.
45. LIEBOWITZ MR, SCHNEIER F, CAMPEAS R et al. Phenelzine versus atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry 1992 ; 49: 290-300.
46. LINKS PS, STEINER M, BOIAGO I et al. Lithium therapy for borderline patients : preliminary findings. J Personality Dis 1990 ; 4 : 173-81.
47. LINKS PS, HESLEGRAVE R, VILLELA J. Psychopharmacological management of personality disorders : an outcome-focused model. In : Silk KR, ed. Biology of personality disorders. Washington : American Psychiatric Press, 1998 ; 93-127.
48. LORANGER AW, SARTORIUS N, ANDREOLI A et al. The International Personality Disorder Examination. The World Health Organization/Alcohol, Drug Abuse, and Mental Health Administration International pilot study of personality disorders. Arch Gen Psychiatry 1994 ; 51 : 215-24.
49. MCCRAE RR, COSTA PT. Toward a new generation of personality theories : theoretical contexts for the five-factor model. In : Wiggins JS, ed. The five-factor model of personality. Theoretical perspectives. New York : The Guilford Press, 1996 ; 51-87.
50. MCGEE MD. Cessation of self-mutilation in a patient with borderline personality disorder treated with naltrexone. J Clin Psychiatry 1997 ; 58 : 32-3.
51. MARKOVITZ PJ, CALABRESE JR, SCHULZSC et al. Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry 1991 ; 148 : 1064-7.
52. MARKOVITZ PJ, WAGNER SC. Venlafaxine in the treatment of borderline personality disorder. Psychopharmacol Bull 1995 ; 31 : 773-7.
53. MATTES JA. Psychopharmacology of temper outbursts : a review. J Nerv Ment Dis 1986 ; 174 : 464-79.
54. MAVISSAKALIAN M, HAMANN MS. DSM III personality disorder in agoraphobia. II. Changes with treatment. Compr Psychiatry 1987 ; 28 : 356-61.
55. MONTGOMERY AS, MONTGOMERY D. Pharmacological prevention of suicidal behavior. J Affect Disord 1982 ; 4 : 291-8.
56. MOSS HB, YAO JK, PANZAK GL. Serotonergic responsitivity and behavioral dimensions in antisocial personality disorder with substance abuse. Biol Psychiatry 1990 ; 28 : 325-38.
57. NORDEN MJ. Fluoxetine in borderline personality disorder. Prog Neuro Psychopharmacol Biol Psychiat 1989 ; 13 : 885-93.
58. NOYES R Jr, REICH JH, SUELZER M et al. Personality traits associated with panic disorder : change associated with treatment. Compr Psychiatry 1991 ; 32 : 283-94.
59. OSTENDORF F, ANGLEITNER A. A comparison of different instruments proposed to measure the big five. Eur J Applied Psychol 1994; 44 : 45-53.
60. PARSONS B, QUITKIN FM, MCGRATH PJ et al. Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacol Bull 1989 ; 25 : 524-34.
61. PELISSOLO A, LEPINE JP. Traduction française et premières études de validation du questionnaire de personnalité TCI. Ann Med Psychol 1997 ; 155 : 497-508.
62. PERON-MAGNAN P. Tempérament et dépression. In : Olié JP, Poirier MF, Lôo H, eds. Les maladies dépressives. Paris : Flammarion, 1995 ; 183-91.
63. PERRY JC. Problems and considerations in the valid assessment of personality disorders. Am J Psychiatry 1992 ; 149 : 1645-53.
64. PILKONIS PA, HEAPE CL, PROIETTI JM et al. The reliability and validity of two structured diagnostic interviews for personality disorders. Arch Gen Psychiatry 1995 ; 52 : 1025-33.
65. RAMMSAYER T, NETTER P. Personality related differences in response to 5-HT uptake inhibition, lnt J Neurosci 1990 ; 55 : 99-106.
66. REICH J, NOYES R, YATES W. Alprazolam treatment of avoidant personality traits in social phobic patients. J Clin Psychiatry 1989 ; 50 : 91-5.
67. REICH JH, GREEN AI. Effect of personality disorders on outcome of treatment. J Nerv Ment Dis 1991 ; 179 : 74-82.
68. RICCIARDI JN, BAER L, JENIKE MA et al. Changes in DSM III-R axis II diagnosis following treatment of obsessive-compulsive disorder. Am J Psychiatry 1992 ; 149 : 829-31.
69. RIFKIN A, QUITKIN F, CARILLO C et al. Lithium carbonate in emotionally unstable character disorder. Arch Gen Psychiatry 1972 ; 27 : 519-23.
70. ROLLAND JP. Validité de construct de «marqueurs »des dimensions de personnalité du modèle en cinq facteurs. J Eur Psychol Appliquée 1994; 44 : 317-37.
71. ROTH AS, OSTROFF RB, HUFFMAN RE. Naltrexone as a treatment for repetitive self-injurious behavior : an open-label trial. J Clin Psychiatry 1996 ; 57 : 233-7.
72. SALZMAN C, WOLFSON AN, SCHATZBERG A et al. Effects of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995 ; 15 : 23-9.
73. SERBAN G, SIEGEL S. Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. Am J Psychiatry 1984 ; 141 : 1455-8.
74. SHEARD MH, MARINI SL, BRIDGES CI ef al. The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry 1976 ; 133 : 1409-13.
75. SIEVER LJ, COCCARO EF, ZEMISHLANY EF et al. Psychobiology of personality disorders : pharmacologie implications. Psychopharmacol Bull 1987 ; 23 : 333-6.
76. SIEVER LJ, DAVIS KL. A psychobiological perspective of the personality disorders. Am J Psychiatry 1991 ; 148 : 1647-58.
77. SOLOFF PH, GEORGE A, NATHAN RW et al. Amitriptyline versus haloperidol in borderlines : final outcomes and predictors of response. J Clin Psychopharmacol 1989 ; 9 : 238-6.
78. SOLOFF PH, CORNELIUS J, GEORGE A et al. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 1993 ; 50 : 377-85.
79. SOLOFF PH. Is there any drug treatment of choice for the borderline patient ? Acta Psychiatr Scand Suppl 1994 ; 379 : 50-5.
80. SOLOFF PH, SIEVER L, COWDRY R et al. Evaluation of pharmacologie treatments in personality disorders. In : Prien RF, Robinson DS, eds. Clinical evaluation of psychotropic drugs : principles and guidelines. New York : Raven Press, 1994 ; 651-73.
81. SOLOFF PH. Symptom-oriented psychopharmacology for personality disorders. New York : Paper presented at the Annual Meeting of the American Psychiatric Association, 1996.
82. SPITZER RL, FLEISS JL. A re-analysis of the reliability of psychiatric diagnosis. Br J Psychiat 1974 ; 125 : 341-7.
83. STANGL D, PFOHL B, ZIMMERMAN M et al. A structured interview for the DSM III personality disorders : a preliminary report. Arch Gen Psychiatry 1985; 42 : 591-6.
84. STEIN G. Drug treatment of the personality disorders. Br J Psychiatry 1992; 161 : 167-84.
85. STEIN DJ, SIMEON D, FRENKEL MJ et al. An open trial of valproate in borderline personality disorder. J Clin Psychiatry 1995 ; 56 : 506-10.
86. STONE MH. Treatment of borderline patients : a pragmatic approach. Psychiatr Clin North Am 1990 ; 13 : 265-85.
87. TEICHER MH, GLOD CA, AARSONSON ST et al. Open assessment of the safety and the efficacy of thioridazine in the treatment of patients with borderline personality disorder. Psychopharmacol Bull 1989 ; 25 : 535-49.
88. THIBAUT F, COLONNA L. Lithium et agressivité chez l'adulte. Encephale 1992 ; 18 : 193-8.
89. THIBAUT F, COLONNA L. Efficacité anti-agressive des bêta-bloquants. Encephale 1993 ; 14 : 263-7.
90. TYRER P. Drug treatment of personality disorder. Psychiatr Bull 1998 ; 22 : 242-4.
91. VANELLE JM, ATTAR-LEVY D, POIRIER MF et al. Controlled efficacy study of fluoxetine in dysthymia. Br J Psychiatry 1997 ; 170 : 345-50.
92. VERSIANI M, NARDI AE, FIGUEIRA I. Pharmacotherapy of dysthymia : review and new findings. Eur Psychiatry 1998 ; 13 : 203-9.
93. WILENS TE, BIEDERMAN J, SPENCER TJ et al. Pharmacotherapy of adult attention deficit/hyperactivity disorder : a review. J Clin Psychopharmacol 1995 ; 15 : 270-9.
94. YUDOFSKY SC, SILVER JM, SCHNEIDER SE. Pharmacologic treatment of aggression. Psychiatr Ann 1987 ; 17 : 397-406.
95. ZIMMERMAN M. Diagnosing personality disorders. A review of issues and research methods. Arch Gen Psychiatry 1994 ; 51 : 225-45.